European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"α_vβ₆-integrin targeted [⁶⁸Ga]Ga-Trivehexin PET/CT imaging of a rare bronchial mucoepidermoid carcinoma.","authors":"Huiqin Wu, Ling Li, Zhiwei Xiao, Chongjiao Li, Yong He","doi":"10.1007/s00259-024-06974-6","DOIUrl":"https://doi.org/10.1007/s00259-024-06974-6","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smaller is better? Compact vs. Conventional gamma camera for sentinel lymph node localization in patients with breast cancer.","authors":"Alexandra Lazar, Fabrizia Gelardi, Andrea Sagona, Marcello Rodari, Lorenzo Leonardi, Roberto Massari, Annunziata D'Elia, Andrea Soluri, Arturo Chiti, Lidija Antunovic","doi":"10.1007/s00259-024-06970-w","DOIUrl":"https://doi.org/10.1007/s00259-024-06970-w","url":null,"abstract":"<p><strong>Purpose: </strong>Sentinel lymph node biopsy (SLNB) has been recognized as \"the gold standard\" for axillary staging in early breast cancer patients with clinically negative lymph nodes, resulting in significant morbidity decrease and quality of life improvement. This study aims to validate the performance of a newly developed handheld portable gamma camera (PGC) produced by Imagensys (Italy), in detecting and locating sentinel lymph nodes (SLNs) during the preoperative and intraoperative phases in breast cancer patients compared to conventional lymphoscintigraphy.</p><p><strong>Methods: </strong>Adult female patients with histologically confirmed breast cancer, candidates for surgery and SLNB, were prospectively enrolled in this open-label, pre-marketing clinical trial. All patients underwent pre- operative assessment using both the PGC and conventional lymphoscintigraphy. The performance of the two devices was compared using the Poisson regression model for incidence rate ratios (IRRs). The intrinsic sensitivity of the devices was compared using the Wilcoxon Ranked Sign Test. The utility of PGC during intra-operative procedures was also evaluated. The manoeuvrability of the devices was evaluated using operator-satisfaction questioner.</p><p><strong>Results: </strong>Sixty-eight patients (median age 50 years, BMI 21.4) were enrolled, including two patients with bilateral breast cancer, who underwent SLNB on both axillae. The PGC demonstrated superior preoperative lymph node detection rate (IRR 8.01, 95% CI 6.11-10.50; p < 0.0001) and intrinsic device sensitivity (mean counts per second 409 ± 286 vs. 255 ± 1173 for conventional device, p = 0.0003) compared to the conventional gamma camera. Intra-operative assessment with PGC was performed in 62 patients and no additional lymph nodes were visualised. However, the conventional gamma camera demonstrated superior manoeuvrability (p < 0.0001).</p><p><strong>Conclusion: </strong>The PGC handheld gamma camera showed promising results for preoperative SLN assessment in patients with breast cancer. The limited manoeuvrability may be related to the operator's experience leading to higher inter-operator variability. Appropriate training and frequent use of nuclear medicine and surgical equipment could overcome this limitation.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined brain and spinal FDG PET in the differentiation between ALS and ALS mimics - correction and additional validation study.","authors":"Donatienne Van Weehaeghe, Martijn Devrome, Joke de Vocht, Pegah Masrori, Georg Schramm, Wies Deckers, Kristof Baete, Caro De Weerdt, Philip Van Damme, Michel Koole, Koen Van Laere","doi":"10.1007/s00259-024-06957-7","DOIUrl":"https://doi.org/10.1007/s00259-024-06957-7","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experience of rescue therapy with [¹⁷⁷Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [¹⁷⁷Lu]Lu-PSMA-I&T.","authors":"Alexander Gäble, Alexander Dierks, Andreas Rinscheid, Marianne Patt, Georgine Wienand, Christian H Pfob, Malte Kircher, Kazuhito Fukushima, Ana Antić Nikolić, Johanna S Enke, Tilman Janzen, Julie Steinestel, Hildegard Kempter, Martin Trepel, Dorothea Weckermann, Constantin Lapa, Ralph A Bundschuh","doi":"10.1007/s00259-024-06959-5","DOIUrl":"https://doi.org/10.1007/s00259-024-06959-5","url":null,"abstract":"<p><strong>Purpose: </strong>Radioligand therapy is an increasingly important option for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). Radiohybrid ligands targeting prostate-specific membrane antigen (PSMA) are a novel group of theranostic radioligand therapy agents for which higher tumour absorbed radiation doses have been demonstrated compared to established PSMA ligands. Here, we report data from ten patients who were treated within a compassionate use program with the radiohybrid PSMA-ligand [¹⁷⁷Lu]Lu-rhPSMA-10.1 after experiencing disease progression under treatment with [¹⁷⁷Lu]Lu-PSMA-I&T.</p><p><strong>Methods: </strong>Ten patients with advanced PSMA-positive prostate cancer who showed progression under treatment with [¹⁷⁷Lu]Lu-PSMA-I&T received up to three cycles of rescue therapy with [¹⁷⁷Lu]Lu-rhPSMA-10.1 (7.4-8.1 GBq per cycle). Efficacy (PSA response according to PCWG3 and RECIP) and overall survival were evaluated. Adverse events were recorded from first application.</p><p><strong>Results: </strong>Despite progression with [¹⁷⁷Lu]Lu-PSMA-I&T, after the first cycle of [¹⁷⁷Lu]Lu-rhPSMA-10.1 rescue therapy, five patients (50%) showed a decrease in serum PSA level. In imaging, three of the ten patients (30%) showed a partial radiologic response. Four of the five patients with a decrease of serum PSA under [¹⁷⁷Lu]Lu-rhPSMA-10.1 had initially responded to treatment with [¹⁷⁷Lu]Lu-PSMA-I&T but had become resistant. However, the remaining patient had shown continuous disease progression during [¹⁷⁷Lu]Lu-PSMA-I&T therapy but showed an immediate response to [¹⁷⁷Lu]Lu-rhPSMA-10.1. The additional treatment with [¹⁷⁷Lu]Lu-rhPSMA-10.1 was generally well tolerated by all patients.</p><p><strong>Conclusions: </strong>Patients showing tumour progression while receiving [¹⁷⁷Lu]Lu-PSMA-I&T radioligand therapy may benefit from rescue therapy with the novel radiohybrid PSMA ligand, [¹⁷⁷Lu]Lu-rhPSMA-10.1. Higher tumour absorbed radiation doses with [¹⁷⁷Lu]Lu-rhPSMA-10.1 may overcome primary and acquired radiation resistance.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of rechallenge [¹⁷⁷Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study).","authors":"Florian Rosar, Joelle Schuler, Caroline Burgard, Arne Blickle, Mark Bartholomä, Stephan Maus, Sven Petto, Fadi Khreish, Andrea Schaefer, Samer Ezziddin","doi":"10.1007/s00259-024-06825-4","DOIUrl":"10.1007/s00259-024-06825-4","url":null,"abstract":"<p><strong>Aim: </strong>Rechallenge of [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy (RLT) was proposed for patients who initially responded to PSMA-RLT experiencing partial remission, but relapsed into progression after a certain period of remission. However, only limited data is available regarding this approach. In this study, we analyzed the efficacy and safety profile of one or more series of [¹⁷⁷Lu]Lu-PSMA-617 RLT rechallenge in patients from a prospective registry (REALITY Study, NCT04833517) after they initially benefited from PSMA-RLT.</p><p><strong>Methods: </strong>Forty-seven patients with metastatic castration-resistant prostate cancer (mCRPC) who had biochemical response to initial [¹⁷⁷Lu]Lu-PSMA-617 RLT followed by disease progression received at least one (up to three) series of [¹⁷⁷Lu]Lu-PSMA-617 RLT rechallenge. Biochemical response rates based on prostate-specific antigen (PSA) serum value, PSA-based progression-free survival (PFS) and overall survival (OS) were calculated. Adverse events of the treatment were assessed according to 'common terminology criteria for adverse events' (CTCAE).</p><p><strong>Results: </strong>After one series of RLT rechallenge, a PSA decline of at least 50% was achieved in 27/47 patients (57.4%). The median PFS of all patients was 8.7 mo and the median OS was 22.7 mo, each calculated from the administration of the first rechallenge series. Patients who responded (PSA decline > 50%) to the rechallenge showed a median OS of 27.3 mo. Regarding PFS, a significant correlation (r = 0.4128, p = 0.0323) was found for these patients comparing initial and rechallenge RLT. Ten patients received a second and 3 patients received a third rechallenge series with 8/10 and 3/3 patients responding to repeated RLT rechallenge. No severe deterioration of adverse events rated by CTCAE criteria was observed.</p><p><strong>Conclusion: </strong>[¹⁷⁷Lu]Lu-PSMA-617 RLT rechallenge is associated with significant PSA response and encouraging survival outcome as well as a very favourable safety profile and should therefore be considered as a straight-forward treatment option in mCRPC patients, who previously benefited from PSMA-RLT.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Powering the engine of nuclear medicine: insights from the next generation congress (Milan, 2024).","authors":"Giulia Santo, Alberto Miceli","doi":"10.1007/s00259-024-06867-8","DOIUrl":"10.1007/s00259-024-06867-8","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noradrenergic cardiac denervation is associated with gait velocity in Parkinson disease: a dual ligand PET study.","authors":"G Carli, P Kanel, S Roytman, C Pongmala, R L Albin, D M Raffel, P J H Scott, N I Bohnen","doi":"10.1007/s00259-024-06822-7","DOIUrl":"10.1007/s00259-024-06822-7","url":null,"abstract":"<p><strong>Purpose: </strong>Preliminary data suggest that gait abnormalities in Parkinson disease (PD) may be associated with sympathetic cardiac denervation. No kinematic gait studies were performed to confirm this observation. We aimed to correlate spatiotemporal kinematic gait parameters with cardiac sympathetic denervation as determined by cardiac [¹¹C]HED PET in PD.</p><p><strong>Methods: </strong>Retrospective database analysis of 27 PD patients with cardiac sympathetic denervation. All patients underwent spatiotemporal kinematic gait assessment (medication 'off' state), cardiac [¹¹C]HED and dopaminergic brain [¹¹C]DTBZ PET scans. We employed a hierarchical regression approach to examine associations between the extent of cardiac denervation, dopaminergic nigrostriatal neurodegeneration, and three gait parameters - velocity, step length and cadence.</p><p><strong>Results: </strong>More extensive cardiac denervation was associated with slower velocity (estimate: -1.034, 95% CI [-1.65, -0.42], p = 0.002), shorter step length (estimate: -0.818, 95% CI [-1.43, -0.21], p = 0.011) and lower cadence (estimate: -0.752, 95% CI [-1.28, -0.23], p = 0.007) explaining alone 30% (Adjusted-R²: 0.297), 20% (Adjusted-R²: 0.202) and 23% (Adjusted-R²: 0.227) of the variability, respecivetly. These associations remained independent of striatal dopaminergic impairment and confounding factors such as age, Hoehn and Yahr (HY) stages, peripheral neuropathy, cognition, and autonomic symptoms. In contrast, striatal dopaminergic denervation was significantly associated with step length (estimate: 0.883, 95% CI [0.29, 1.48], p = 0.005), explaining about 24% of the variability but was dependent of HY stage.</p><p><strong>Conclusions: </strong>More severe cardiac noradrenergic denervation was associated with lower gait velocity, independent of striatal dopaminergic denervation and HY stage, impacting both step length and cadence. These results suggest independent contributions of the peripheral autonomic system degeneration on gait dynsfunction in PD.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesis, preclinical assessment, and first-in-human study of [¹⁸F]d₄-FET for brain tumor imaging.","authors":"Lu Hou, Zhiyong Chen, Fanfan Chen, Lianghe Sheng, Weijian Ye, Yingchu Dai, Xiaoyu Guo, Chenchen Dong, Guocong Li, Kai Liao, Yinlong Li, Jie Ma, Huiyi Wei, Wenqing Ran, Jingjie Shang, Xueying Ling, Jimmy S Patel, Steven H Liang, Hao Xu, Lu Wang","doi":"10.1007/s00259-024-06964-8","DOIUrl":"https://doi.org/10.1007/s00259-024-06964-8","url":null,"abstract":"<p><strong>Purpose: </strong>Tumor-to-background ratio (TBR) is a critical metric in oncologic PET imaging. This study aims to enhance the TBR of [¹⁸F]FET in brain tumor imaging by substituting deuterium (\"D\") for hydrogen (\"H\"), thereby improving the diagnostic sensitivity and accuracy.</p><p><strong>Methods: </strong>[¹⁸F]d₄-FET was synthesised by two automated radiochemistry modules. Biodistribution studies and imaging efficacy were evaluated in vivo  and ex vivo in rodent models, while metabolic stability and radiation dosimetry were assessed in non-human primates. Additionally, preliminary imaging evaluations were carried out in five brain tumor patients: three glioma patients underwent imaging with both [¹⁸F]d₄-FET and [¹⁸F]FET, and two patients with brain metastases were imaged using [¹⁸F]d₄-FET and [¹⁸F]FDG.</p><p><strong>Results: </strong>[¹⁸F]d₄-FET demonstrated high radiochemical purity and yield. PET/MRI in rodent models demonstrated superior TBR for [¹⁸F]d₄-FET compared to [¹⁸F]FET, and autoradiography showed tumor margins that correlated well with pathological extents. Studies in cynomolgus monkeys indicated comparable in vivo stability and effective dose with [¹⁸F]FET. In glioma patients, [¹⁸F]d₄-FET showed enhanced TBR, while in patients with brain metastases, [¹⁸F]d₄-FET displayed superior lesion delineation compared to [¹⁸F]FDG, especially in smaller metastatic sites.</p><p><strong>Conclusion: </strong>We successfully synthesized the novel PET radiotracer [¹⁸F]d₄-FET, which retains the advantageous properties of [¹⁸F]FET while potentially enhancing TBR for glioma imaging. Preliminary studies indicate excellent stability, efficacy, and sensitivity of [¹⁸F]d₄-FET, suggesting its potential in clinical evaluations of brain tumors.</p><p><strong>Trial registration: </strong>ChiCTR2400081576, registration date: 2024-03-05, https://www.chictr.org.cn/bin/project/edit?pid=206162.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The complete metabolic/molecular response to chemotherapy combined with [¹⁷⁷Lu]Lu-FAP-2286 in metastatic breast cancer.","authors":"Seyedeh Somayyeh Banihashemian, Mohammad Esmaeil Akbari, Ghazal Norouzi, Babak Nikkholgh, Hamidreza Amini, Ghasemali Divband, Elahe Pirayesh, Abdolghafar Abolhosseini Shahrnoy, Reza Nami, Meysam Nasiri","doi":"10.1007/s00259-024-06817-4","DOIUrl":"10.1007/s00259-024-06817-4","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical SPECT and PET: Joint EANM and ESMI procedure guideline for implementing an efficient quality control programme.","authors":"Christian Vanhove, Michel Koole, Pedro Fragoso Costa, Margret Schottelius, Julia Mannheim, Claudia Kuntner, Geoff Warnock, Wendy McDougald, Adriana Tavares, Monique Bernsen","doi":"10.1007/s00259-024-06824-5","DOIUrl":"10.1007/s00259-024-06824-5","url":null,"abstract":"<p><p>The aim of this guideline is to provide recommendations for the implementation of an effective and efficient quality control (QC) programme for SPECT and PET systems in a preclinical imaging lab. These recommendations aim to strengthen the translational power of preclinical imaging results obtained using preclinical SPECT and PET. As for clinical imaging, reliability, reproducibility, and repeatability are essential when groups of animals are used in a longitudinal imaging experiment. The larger the variability of the imaging endpoint, the more animals are needed to be able to observe statistically significant differences between groups. Therefore, preclinical imaging requires quality control procedures to maintain reliability, reproducibility, and repeatability of imaging procedures, and to ensure the accuracy and precision of SPECT and PET quantification. While the Physics Committee of the European Association of Nuclear Medicine (EANM) has already published excellent procedure guidelines for Routine Quality Control Recommendations for Nuclear Medicine Instrumentation that also includes procedures for small animal PET systems, and important steps have already been made concerning preclinical quality control aspects, this new guideline provides a review and update of these previous guidelines such that guidelines are also adapted to new technological developments.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}